Recursion Pharmaceuticals (RXRX) stock surged after the company significantly beat Street forecasts with its Q4 2025 results.

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

The Pentagon had kept trying to leave itself little escape hatches in the agreements that it proposed to Anthropic. It would ...

How Fast Will A.I. Agents Rip Through the Economy? transcript The thing about covering A.I. over the past few years is it ...

Overview: The global Artificial Intelligence (AI) in drug discovery market is projected to grow at a rate of 25-30% over the ...